Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 20/20 | 0.59 |
| ▸ | MTNR1B | P49286 | 14/20 | 0.59 |
| ▸ | HTR2C | P28335 | 7/20 | 0.53 |
| ▸ | NQO2 | P16083 | 1/20 | 0.46 |
| ▸ | HTR2B | P41595 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29032172 | 0.89 | MTNR1A (0.53) | MTNR1AMTNR1BHTR2CNQO2 | |
| SCHEMBL3640537 | 0.88 | MTNR1A (0.53) | MTNR1AMTNR1BHTR2CNQO2HTR2B | |
| SCHEMBL8858633 | 0.84 | ALDH1A1 (0.44) | MTNR1AMTNR1B | |
| SCHEMBL5121759 | 0.79 | MTNR1A (0.55) | MTNR1AMTNR1BHTR2CNQO2HTR2B | |
| SCHEMBL4583332 | 0.79 | MTNR1A (0.54) | MTNR1AMTNR1BHTR2CNQO2HTR2B | |
| SCHEMBL10565825 | 0.76 | MTNR1A (0.56) | MTNR1AMTNR1BHTR2CNQO2HTR2B | |
| SCHEMBL17091260 | 0.76 | MTNR1A (0.53) | MTNR1AMTNR1BHTR2CNQO2 | |
| SCHEMBL31724242 | 0.75 | L3MBTL1 (0.48) | MTNR1AMTNR1B | |
| SCHEMBL5432800 | 0.75 | L3MBTL1 (0.48) | MTNR1AMTNR1B | |
| SCHEMBL299431 | 0.74 | PTGS2 (0.57) | MTNR1AMTNR1BHTR2CNQO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100137446-A1 | NAPHTHALENE COMPOUNDS, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | LES LABORATOIRES SERVIER (FR) | 2010-06-03 | — | — | US | disclosed |
| EP-1873140-B1 | New naphthalene derivatives, method of preparing same and pharmaceutical compositions containing them | SERVIER LAB (FR) | 2009-09-30 | — | — | EP | disclosed |
| US-7462741-B2 | Naphthalene compounds | LES LABORATOIRES SERVIER (FR) | 2008-12-09 | — | — | US | disclosed |
| US-7462741-B2 | Naphthalene compounds | LES LABORATOIRES SERVIER (FR) | 2008-12-09 | — | — | US | disclosed |
| US-7462741-B2 | Naphthalene compounds | LES LABORATOIRES SERVIER (FR) | 2008-12-09 | — | — | US | disclosed |
| US-7435850-B2 | Naphthalene compounds | LES LABORATOIRES SERVIER (FR) | 2008-10-14 | — | — | US | disclosed |
| US-7435850-B2 | Naphthalene compounds | LES LABORATOIRES SERVIER (FR) | 2008-10-14 | — | — | US | disclosed |
| US-7435850-B2 | Naphthalene compounds | LES LABORATOIRES SERVIER (FR) | 2008-10-14 | — | — | US | disclosed |
| US-20080004350-A1 | Naphthalene compounds | LES LABORATOIRES SERVIER (FR) | 2008-01-03 | — | — | US | disclosed |
| US-20080004350-A1 | Naphthalene compounds | LES LABORATOIRES SERVIER (FR) | 2008-01-03 | — | — | US | disclosed |
| US-20080004350-A1 | Naphthalene compounds | LES LABORATOIRES SERVIER (FR) | 2008-01-03 | — | — | US | disclosed |
| US-20080004349-A1 | e.g. N-[(2S)-3-hydroxy-2-(7-methoxy-1-naphthyl)propyl]propanamide; N-[(2S)-3-hydroxy-2-(7-methoxy-1-naphthyl)propyl]propanamide; melatonin receptor antagonist; antidepressant, anxiolytic agent; sleep disorders, stress, cardiovascular and digestive system pathologies, schizophrenia, obesity, epilepsy | LES LABORATOIRES SERVIER (FR) | 2008-01-03 | — | — | US | disclosed |
| US-20080004349-A1 | e.g. N-[(2S)-3-hydroxy-2-(7-methoxy-1-naphthyl)propyl]propanamide; N-[(2S)-3-hydroxy-2-(7-methoxy-1-naphthyl)propyl]propanamide; melatonin receptor antagonist; antidepressant, anxiolytic agent; sleep disorders, stress, cardiovascular and digestive system pathologies, schizophrenia, obesity, epilepsy | LES LABORATOIRES SERVIER (FR) | 2008-01-03 | — | — | US | disclosed |
| US-20080004349-A1 | e.g. N-[(2S)-3-hydroxy-2-(7-methoxy-1-naphthyl)propyl]propanamide; N-[(2S)-3-hydroxy-2-(7-methoxy-1-naphthyl)propyl]propanamide; melatonin receptor antagonist; antidepressant, anxiolytic agent; sleep disorders, stress, cardiovascular and digestive system pathologies, schizophrenia, obesity, epilepsy | LES LABORATOIRES SERVIER (FR) | 2008-01-03 | — | — | US | disclosed |
| US-20080004348-A1 | Naphthalene compounds | LES LABORATOIRES SERVIER (FR) | 2008-01-03 | — | — | US | disclosed |
| WO-2008000967-A1 | NOVEL NAPHTHALENIC DERIVATIVES, METHOD FOR THE PREPARATION THEREOF, AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | LES LABORATOIRES SERVIER (FR) | 2008-01-03 | — | — | WO | disclosed |
| WO-2008000968-A1 | NOVEL NAPHTHALENIC DERIVATIVES, METHOD FOR THE PREPARATION THEREOF, AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | LES LABORATOIRES SERVIER (FR) | 2008-01-03 | — | — | WO | disclosed |
| EP-1873140-A1 | New naphthalene derivatives, method of preparing same and pharmaceutical compositions containing them | Les Laboratoires Servier (FR) | 2008-01-02 | — | — | EP | disclosed |
| EP-1873139-A1 | New naphthalene derivatives, method of preparing same and pharmaceutical compositions containing them | Les Laboratoires Servier (FR) | 2008-01-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137446-A1 | NAPHTHALENE COMPOUNDS, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | MTNR1A, MTNR1B, AHR | MTNR1A 1/4885MTNR1B 2/4885HTR2C 42/4885 |
| US-20080004349-A1 | e.g. N-[(2S)-3-hydroxy-2-(7-methoxy-1-naphthyl)propyl]propanamide; N-[(2S)-3-hydroxy-2-(7-methoxy-1-naphthyl)propyl]propanamide; melatonin receptor antagonist; antidepressant, anxiolytic agent; sleep disorders, stress, cardiovascular and digestive system pathologies, schizophrenia, obesity, epilepsy | MTNR1A, MTNR1B, TPH1 | MTNR1A 1/4885MTNR1B 2/4885HTR2C 7/4885 |
| US-20080004348-A1 | Naphthalene compounds | MTNR1A, MTNR1B, CNR1 | MTNR1A 1/4885MTNR1B 2/4885HTR2C 53/4885 |
| US-20080004350-A1 | Naphthalene compounds | MTNR1A, MTNR1B, CYP11B2 | MTNR1A 1/4885MTNR1B 2/4885HTR2C 164/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.